Arginine

References

1. ^ a b Figueroa A, et al. Watermelon extract supplementation reduces ankle blood pressure and carotid augmentation index in obese adults with prehypertension or hypertension. Am J Hypertens. (2012)
2. ^ a b Corpas E, et al. Oral arginine-lysine does not increase growth hormone or insulin-like growth factor-I in old men. J Gerontol. (1993)
3. ^ a b Buford BN, Koch AJ. Glycine-arginine-alpha-ketoisocaproic acid improves performance of repeated cycling sprints. Med Sci Sports Exerc. (2004)
4. ^ a b Stevens BR, et al. High-intensity dynamic human muscle performance enhanced by a metabolic intervention. Med Sci Sports Exerc. (2000)
5. ^ Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. (1998)
6. ^ Arginine metabolism in mammals.
7. ^ Malinauskas BM, et al. Supplements of interest for sport-related injury and sources of supplement information among college athletes. Adv Med Sci. (2007)
8. ^ Tharakan JF, et al. Adaptation to a long term (4 weeks) arginine- and precursor (glutamate, proline and aspartate)-free diet. Clin Nutr. (2008)
9. ^ a b c de Jonge WJ, et al. Overexpression of arginase I in enterocytes of transgenic mice elicits a selective arginine deficiency and affects skin, muscle, and lymphoid development. Am J Clin Nutr. (2002)
10. ^ de Jonge WJ, et al. Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic mice. J Clin Invest. (2002)
11. ^ de Jonge WJ, et al. Overexpression of arginase alters circulating and tissue amino acids and guanidino compounds and affects neuromotor behavior in mice. J Nutr. (2001)
12. ^ Kwikkers KL, et al. Effect of arginine deficiency on arginine-dependent post-translational protein modifications in mice. Br J Nutr. (2005)
13. ^ a b Morris CR, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. (2005)
14. ^ a b Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity.
15. ^ Schramm L, et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int. (2002)
16. ^ a b Adverse Gastrointestinal Effects of Arginine and Related Amino Acids.
17. ^ Morris SM Jr. Recent advances in arginine metabolism. Curr Opin Clin Nutr Metab Care. (2004)
18. ^ De Bandt JP, et al. Metabolism of ornithine, alpha-ketoglutarate and arginine in isolated perfused rat liver. Br J Nutr. (1995)
19. ^ Curis E, et al. Almost all about citrulline in mammals. Amino Acids. (2005)
20. ^ Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets.
21. ^ a b c Häberle J, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. (2012)
22. ^ Bommarius AS, Makryaleas K, Drauz K. An enzymatic route to L-ornithine from L-arginine–activation and stabilization studies on L-arginase. Biomed Biochim Acta. (1991)
23. ^ Bommarius AS, Drauz K. An enzymatic route to L-ornithine from arginine–activation, selectivity and stabilization of L-arginase. Bioorg Med Chem. (1994)
24. ^ a b Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
25. ^ Dai Z, et al. Nitric oxide and energy metabolism in mammals. Biofactors. (2013)
26. ^ a b Molderings GJ, Haenisch B. Agmatine (decarboxylated L-arginine): physiological role and therapeutic potential. Pharmacol Ther. (2012)
27. ^ Regunathan S, Reis DJ. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. J Neurochem. (2000)
28. ^ Raasch W, et al. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. (1995)
29. ^ Raasch W, et al. Agmatine is widely and unequally distributed in rat organs. Ann N Y Acad Sci. (1995)
30. ^ Li G, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. (1994)
31. ^ a b c d e f g Bode-Böger SM, et al. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol. (1998)
32. ^ a b c d Tangphao O, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol. (1999)
33. ^ White MF, Christensen HN. The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport system. J Biol Chem. (1982)
34. ^ White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J Biol Chem. (1982)
35. ^ MacLeod CL. Regulation of cationic amino acid transporter (CAT) gene expression. Biochem Soc Trans. (1996)
36. ^ MacLeod CL, Finley KD, Kakuda DK. y(+)-type cationic amino acid transport: expression and regulation of the mCAT genes. J Exp Biol. (1994)
37. ^ Identification and Characterization of a Membrane Protein (y+L Amino Acid Transporter-1) That Associates with 4F2hc to Encode the Amino Acid Transport Activity y+L A CANDIDATE GENE FOR LYSINURIC PROTEIN INTOLERANCE.
38. ^ Verrey F, et al. New glycoprotein-associated amino acid transporters. J Membr Biol. (1999)
39. ^ a b c Dall’Asta V, et al. Arginine transport through system y(+)L in cultured human fibroblasts: normal phenotype of cells from LPI subjects. Am J Physiol Cell Physiol. (2000)
40. ^ a b c d e Collier SR, Casey DP, Kanaley JA. Growth hormone responses to varying doses of oral arginine. Growth Horm IGF Res. (2005)
41. ^ a b Jabecka A, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status. Eur Rev Med Pharmacol Sci. (2012)
42. ^ a b c d e Wilson AM, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. (2007)
43. ^ a b Teerlink T. Letter by Teerlink regarding article, “L-arginine supplementation in peripheral arterial disease: no benefit and possible harm”. Circulation. (2008)
44. ^ Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. (1993)
45. ^ Hawkins RD, Kandel ER, Siegelbaum SA. Learning to modulate transmitter release: themes and variations in synaptic plasticity. Annu Rev Neurosci. (1993)
46. ^ a b Huang EP. Synaptic plasticity: a role for nitric oxide in LTP. Curr Biol. (1997)
47. ^ a b Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. (1991)
48. ^ Arancio O, et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell. (1996)
49. ^ Bartus K, Pigott B, Garthwaite J. Cellular targets of nitric oxide in the hippocampus. PLoS One. (2013)
50. ^ a b O’Dell TJ, et al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science. (1994)
51. ^ Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity.
52. ^ a b c Son H, et al. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. (1996)
53. ^ Sakoda T, et al. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol Cell Biochem. (1995)
54. ^ Kantor DB, et al. A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue. Science. (1996)
55. ^ Lameu C, de Camargo AC, Faria M. L-arginine signalling potential in the brain: the peripheral gets central. Recent Pat CNS Drug Discov. (2009)
56. ^ Flam BR, Eichler DC, Solomonson LP. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric Oxide. (2007)
57. ^ Xie L, Gross SS. Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. J Biol Chem. (1997)
58. ^ Husson A, et al. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem. (2003)
59. ^ Matarredona ER, et al. Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zone. Brain Res. (2004)
60. ^ Stoop R, Poo MM. Synaptic modulation by neurotrophic factors. Prog Brain Res. (1996)
61. ^ Lo DC. Neurotrophic factors and synaptic plasticity. Neuron. (1995)
62. ^ Hsieh HY, et al. Nitric oxide regulates BDNF release from nodose ganglion neurons in a pattern-dependent and cGMP-independent manner. J Neurosci Res. (2010)
63. ^ Lameu C, et al. Interactions between the NO-citrulline cycle and brain-derived neurotrophic factor in differentiation of neural stem cells. J Biol Chem. (2012)
64. ^ Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. (1993)
65. ^ a b Jezova D, et al. Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifies neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. Nutr Neurosci. (2005)
66. ^ Jezova D, et al. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry. (2004)
67. ^ Smriga M, et al. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res. (2007)
68. ^ Dietary L-Lysine Deficiency Increases Stress-Induced Anxiety and Fecal Excretion in Rats.
69. ^ Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in northwest Syria.
70. ^ Chang YF, Gao XM. L-lysine is a barbiturate-like anticonvulsant and modulator of the benzodiazepine receptor. Neurochem Res. (1995)
71. ^ Hasler WL. Lysine as a serotonin receptor antagonist: using the diet to modulate gut function. Gastroenterology. (2004)
72. ^ Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc Natl Acad Sci U S A. (2003)
73. ^ Smriga M, Torii K. Prolonged treatment with L-lysine and L-arginine reduces stress-induced anxiety in an elevated plus maze. Nutr Neurosci. (2003)
74. ^ Joung HY, et al. The differential role of NOS inhibitors on stress-induced anxiety and neuroendocrine alterations in the rat. Behav Brain Res. (2012)
75. ^ Malinski T. Nitric oxide and nitroxidative stress in Alzheimer’s disease. J Alzheimers Dis. (2007)
76. ^ McCann SM, et al. The nitric oxide theory of aging revisited. Ann N Y Acad Sci. (2005)
77. ^ a b Calabrese V, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. (2007)
78. ^ Rushaidhi M, et al. Aging affects L-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels. Neuroscience. (2012)
79. ^ Liu P, Jing Y, Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structures. Neuroscience. (2009)
80. ^ Neural plasticity in the ageing brain.
81. ^ Greenwood PM. Functional plasticity in cognitive aging: review and hypothesis. Neuropsychology. (2007)
82. ^ a b Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol. (1997)
83. ^ Charles IG, et al. Expression of human nitric oxide synthase isozymes. Methods Enzymol. (1996)
84. ^ Casas JP, et al. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. (2006)
85. ^ Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. (1995)
86. ^ Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. (1993)
87. ^ Masters BS. Nitric oxide synthases: why so complex. Annu Rev Nutr. (1994)
88. ^ Mayer B, et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett. (1991)
89. ^ Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J Biol Chem. (1991)
90. ^ Stuehr DJ, et al. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A. (1991)
91. ^ Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci. (1997)
92. ^ Ghosh DK, Abu-Soud HM, Stuehr DJ. Reconstitution of the second step in NO synthesis using the isolated oxygenase and reductase domains of macrophage NO synthase. Biochemistry. (1995)
93. ^ Lekakis JP, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. (2002)
94. ^ L-Arginine and Atherothrombosis.
95. ^ a b Lucotti P, et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. (2006)
96. ^ a b c d e f Acute L-arginine supplementation reduces the O2 cost of moderate-intensity exercise and enhances high-intensity exercise tolerance.
97. ^ a b Fahs CA, Heffernan KS, Fernhall B. Hemodynamic and vascular response to resistance exercise with L-arginine. Med Sci Sports Exerc. (2009)
98. ^ a b c Tang JE, et al. Bolus arginine supplementation affects neither muscle blood flow nor muscle protein synthesis in young men at rest or after resistance exercise. J Nutr. (2011)
99. ^ a b c Alvares TS, et al. Acute l-arginine supplementation increases muscle blood volume but not strength performance. Appl Physiol Nutr Metab. (2012)
100. ^ Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. (2007)
101. ^ Baydoun AR, et al. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun. (1990)
102. ^ Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. (1988)
103. ^ Cardounel AJ, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. (2007)
104. ^ a b Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells. Free Radic Biol Med. (2002)
105. ^ a b Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. (2007)
106. ^ a b Shin S, Mohan S, Fung HL. Intracellular L-arginine concentration does not determine NO production in endothelial cells: implications on the “L-arginine paradox”. Biochem Biophys Res Commun. (2011)
107. ^ a b c Liu TH, et al. No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletes. J Nutr Biochem. (2009)
108. ^ Tsukahara H, Gordienko DV, Goligorsky MS. Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. Biochem Biophys Res Commun. (1993)
109. ^ a b Joshi MS, et al. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Proc Natl Acad Sci U S A. (2007)
110. ^ a b McDonald KK, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the “arginine paradox”. J Biol Chem. (1997)
111. ^ Zani BG, Bohlen HG. Transport of extracellular l-arginine via cationic amino acid transporter is required during in vivo endothelial nitric oxide production. Am J Physiol Heart Circ Physiol. (2005)
112. ^ Kone BC. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand. (2000)
113. ^ a b Vallance P, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. (1992)
114. ^ a b Böger RH, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. (1998)
115. ^ a b Mittermayer F, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. (2006)
116. ^ ADMA, Endothelial Progenitor Cells, and Cardiovascular Risk.
117. ^ Effects of asymmetric dimethylarginine (ADMA) infusion in humans.
118. ^ Kielstein JT, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. (2004)
119. ^ a b Cooke JP. Asymmetrical dimethylarginine: the Uber marker. Circulation. (2004)
120. ^ Leiper JM, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. (1999)
121. ^ Jacobi J, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation. (2005)
122. ^ Stühlinger MC, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. (2001)
123. ^ Drexler H, et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. (1991)
124. ^ Ito A, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. (1999)
125. ^ Lin KY, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. (2002)
126. ^ Willoughby DS, et al. Effects of 7 days of arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide metabolites, and asymmetric dimethyl arginine after resistance exercise. Int J Sport Nutr Exerc Metab. (2011)
127. ^ a b c d Schwedhelm E, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. (2008)
128. ^ Ochiai M, et al. Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men. Int J Cardiol. (2012)
129. ^ Bode-Böger SM, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. (1996)
130. ^ Sydow K, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. (2004)
131. ^ Witte DR, et al. Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patients. Atherosclerosis. (2005)
132. ^ Lind L. Arterial compliance influences the measurement of flow-mediated vasodilation, but not acetylcholine-mediated forearm blood flow. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. (2007)
133. ^ a b Vasilijevic A, et al. Beneficial effects of L-arginine nitric oxide-producing pathway in rats treated with alloxan. J Physiol. (2007)
134. ^ Méndez JD, Hernández Rde H. L-arginine and polyamine administration protect beta-cells against alloxan diabetogenic effect in Sprague-Dawley rats. Biomed Pharmacother. (2005)
135. ^ a b Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med. (1998)
136. ^ Lindsay RM, et al. N omega-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes. (1995)
137. ^ Kaneto H, et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes. (1995)
138. ^ DiMagno MJ, et al. Secretagogue-stimulated pancreatic secretion is differentially regulated by constitutive NOS isoforms in mice. Am J Physiol Gastrointest Liver Physiol. (2004)
139. ^ a b c Monti LD, et al. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. (2012)
140. ^ Tang WH, et al. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. (2009)
141. ^ Sourij H, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis. (2011)
142. ^ Jabłecka A, et al. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci. (2012)
143. ^ a b Álvares TS, et al. L-Arginine as a potential ergogenic aid in healthy subjects. Sports Med. (2011)
144. ^ Long JH, et al. Arginine supplementation induces myoblast fusion via augmentation of nitric oxide production. J Muscle Res Cell Motil. (2006)
145. ^ Maxwell AJ, et al. L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production. J Appl Physiol. (2001)
146. ^ Schaefer A, et al. L-arginine reduces exercise-induced increase in plasma lactate and ammonia. Int J Sports Med. (2002)
147. ^ Wax B, et al. Acute L-arginine alpha ketoglutarate supplementation fails to improve muscular performance in resistance trained and untrained men. J Int Soc Sports Nutr. (2012)
148. ^ Abel T, et al. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism – a randomized, double-blind, placebo-controlled study. Int J Sports Med. (2005)
149. ^ Colombani PC, et al. Chronic arginine aspartate supplementation in runners reduces total plasma amino acid level at rest and during a marathon run. Eur J Nutr. (1999)
150. ^ McConell GK. Effects of L-arginine supplementation on exercise metabolism. Curr Opin Clin Nutr Metab Care. (2007)
151. ^ McKnight JR, et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids. (2010)
152. ^ a b c d e Zajac A, et al. Arginine and ornithine supplementation increases growth hormone and insulin-like growth factor-1 serum levels after heavy-resistance exercise in strength-trained athletes. J Strength Cond Res. (2010)
153. ^ a b c d Kanaley JA. Growth hormone, arginine and exercise. Curr Opin Clin Nutr Metab Care. (2008)
154. ^ Oral arginine attenuates the growth hormone response to resistance exercise.
155. ^ a b Marcell TJ, et al. Oral arginine does not stimulate basal or augment exercise-induced GH secretion in either young or old adults. J Gerontol A Biol Sci Med Sci. (1999)
156. ^ a b Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise, and aging: the future of therapy for the frail elderly. J Am Geriatr Soc. (1994)
157. ^ a b Fogelholm GM, et al. Low-dose amino acid supplementation: no effects on serum human growth hormone and insulin in male weightlifters. Int J Sport Nutr. (1993)
158. ^ Veldhuis JD, Bowers CY. Regulated recovery of pulsatile growth hormone secretion from negative feedback: a preclinical investigation. Am J Physiol Regul Integr Comp Physiol. (2011)
159. ^ Veldhuis JD, et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res. (2001)
160. ^ Besset A, et al. Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in man. Acta Endocrinol (Copenh). (1982)
161. ^ Barbul A, et al. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery. (1990)
162. ^ Shi HP, et al. Supplemental L-arginine enhances wound healing in diabetic rats. Wound Repair Regen. (2003)
163. ^ Debats IB, et al. Role of arginine in superficial wound healing in man. Nitric Oxide. (2009)
164. ^ Shi HP, et al. Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout mice. Surgery. (2000)
165. ^ Shi HP, et al. Effect of supplemental ornithine on wound healing. J Surg Res. (2002)
166. ^ Campbell B, et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. Nutrition. (2006)
167. ^ Cynober L, et al. Action of ornithine alpha-ketoglutarate, ornithine hydrochloride, and calcium alpha-ketoglutarate on plasma amino acid and hormonal patterns in healthy subjects. J Am Coll Nutr. (1990)
168. ^ a b c Moinard C, et al. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr. (2008)
169. ^ Rougé C, et al. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol. (2007)
170. ^ Thibault R, et al. Oral citrulline does not affect whole body protein metabolism in healthy human volunteers: results of a prospective, randomized, double-blind, cross-over study. Clin Nutr. (2011)
171. ^ Sureda A, et al. L-citrulline-malate influence over branched chain amino acid utilization during exercise. Eur J Appl Physiol. (2010)
172. ^ Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in man after oral administration of amino acids. Curr Med Res Opin. (1981)
173. ^ Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol. (2008)
174. ^ Hellier MD, Holdsworth CD, Perrett D. Dibasic amino acid absorption in man. Gastroenterology. (1973)
175. ^ Izzo AA, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci. (1998)